Can Ki67 and Caspase Predict Molar Progression?

Nagib, Reham M; Zaki, Marwa Ma; Wageh, Alaa; Abdelrazik, Mahmoud Mohamed

doi:10.1080/15513815.2019.1608607

Cited by 3 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ki67 expression was found to be increased with GTD formation in some studies whereas others indicated that there was no such difference [10,[31][32][33]. The effect of Ki67 on GTN progression showed also inconclusive results where some studies showed increased expression in malignant formation whereas others were able to show no difference between GTD and GTN samples [31,34]. Although the diagnostic or prognostic value of Ki67 was previously reported, Ki67 was not significantly different between any of the investigated groups in this study.…”

Section: Discussioncontrasting

confidence: 72%

“…For GTD, Ki67 has inconclusive results. Ki67 expression was found to be increased with GTD formation in some studies whereas others indicated that there was no such difference [10,[31][32][33]. The effect of Ki67 on GTN progression showed also inconclusive results where some studies showed increased expression in malignant formation whereas others were able to show no difference between GTD and GTN samples [31,34].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Discovery of the prognostic marker in the whole blood sample of gestational trophoblastic neoplasia beyond immunohistochemical tissue markers: mdm2

2023

European Journal of Gynaecological Oncology

View full text Add to dashboard Cite

Gestational trophoblastic disease (GTD) is an abnormal trophoblastic proliferation disease that may show malignant progression. Despite reports on the clinical and laboratory parameters for the projection of GTD, there is still a lack of histopathologic or genetic prognostic markers for patients with higher risks of malignant progression and high-risk gestational trophoblastic neoplasia. The primary aim of this study was to identify a marker other than tissue markers for evaluating the progression potential of GTD to gestational trophoblastic neoplasia (GTN). The secondary aim was to determine the tissue marker capacity to detect the progression to neoplasia. The study design was a case-control. The data of 81 patients diagnosed with GTD and 23 control were assessed. Their detailed obstetric and gynecological history were recorded, and their whole blood sample was obtained for genetic evaluation of the mouse double minute 2 (mdm2) gene expression. We also evaluated the curettage specimens for p53, c-erythroblastic oncogene B-2 (c-erbB-2), and ki67 protein expression. The expression of p53 expression was significantly increased in GTD patients and significantly higher in the GTN progressing group than in the spontaneous remission group. Although blood mdm2 gene was significantly different between the low and high-risk GTN subgroups, its expression was not different between the GTD or GTN groups. Additionally, a significant increase in c-erbB-2 was observed in the GTN group. Mdm2 might be a promising blood prognostic factor throughout the course of GTD. p53 and c-erbB-2 might be used as predictive indicators for the early diagnosis of GTN progression. Altogether, these markers may help identify patients with high risks of malignant progression, guide earlier aggressive treatment and increase treatment outcomes.

show abstract

Section: Discussioncontrasting

confidence: 72%

Section: Discussionmentioning

confidence: 99%

Discovery of the prognostic marker in the whole blood sample of gestational trophoblastic neoplasia beyond immunohistochemical tissue markers: mdm2

2023

European Journal of Gynaecological Oncology

View full text Add to dashboard Cite

show abstract

Distinct microRNA profiles for complete hydatidiform moles at risk of malignant progression

Lin

Maestá

Laurent

et al. 2021

American Journal of Obstetrics and Gynecology

View full text Add to dashboard Cite

Molecular Basis of Hydatidiform Moles—A Systematic Review

Bahutair,

Dube,

Kuruba

et al. 2024

IJMS

View full text Add to dashboard Cite

Gestational trophoblastic diseases (GTDs) encompass a spectrum of conditions characterized by abnormal trophoblastic cell growth, ranging from benign molar pregnancies to malignant trophoblastic neoplasms. This systematic review explores the molecular underpinnings of GTDs, focusing on genetic and epigenetic factors that influence disease progression and clinical outcomes. Based on 71 studies identified through systematic search and selection criteria, key findings include dysregulations in tumor suppressor genes such as p53, aberrant apoptotic pathways involving BCL-2 (B-cell lymphoma), and altered expression of growth factor receptors and microRNAs (micro-ribose nucleic acid). These molecular alterations not only differentiate molar pregnancies from normal placental development but also contribute to their clinical behavior, from benign moles to potentially malignant forms. The review synthesizes insights from immunohistochemical studies and molecular analyses to provide a comprehensive understanding of GTD pathogenesis and implications for personalized care strategies.

show abstract

Can Ki67 and Caspase Predict Molar Progression?

Cited by 3 publications

References 11 publications

Discovery of the prognostic marker in the whole blood sample of gestational trophoblastic neoplasia beyond immunohistochemical tissue markers: mdm2

Discovery of the prognostic marker in the whole blood sample of gestational trophoblastic neoplasia beyond immunohistochemical tissue markers: mdm2

Distinct microRNA profiles for complete hydatidiform moles at risk of malignant progression

Molecular Basis of Hydatidiform Moles—A Systematic Review

Contact Info

Product

Resources

About